Fate Therapeutics Overview
Fate Therapeutics Target Price
Analysts' 12-month price predictions for FATE.
Get informed when a big investor buys or sells
+ FollowShare Price
$2.92
Average Target Price
$5.50
88.4% upside
88.4% upside2 analysts in the last 4 months
High: $7 | Low: $4
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-06-08 | H.C. WainwrightDebjit Chattopadhyay | $7 | 139.7% upside |  |
| 2026-05-19 | Jefferies | $4 | 37% upside | |
| 2025-03-06 | Stifel Nicolaus | $3 | 2.7% upside | |
| 2024-11-13 | BMO CapitalEtzer Darout | $5 | 71.2% upside | |
| 2024-08-14 | Stifel NicolausBenjamin Burnett | $5 | 71.2% upside | |
| 2024-06-17 | Piper SandlerEdward Tenthoff | $6 | 105.5% upside | |
| 2024-05-16 | H.C. WainwrightDebjit Chattopadhyay | $5 | 71.2% upside | |
| 2024-05-10 | Piper SandlerEdward Tenthoff | $4 | 37% upside | |
| 2024-05-10 | BMO CapitalEtzer Darout | $6 | 105.5% upside | |
| 2024-05-10 | Canaccord GenuityBill Maughan | $9 | 208.2% upside | |
| 2023-01-09 | Goldman Sachs | $4 | 37% upside | |
| 2023-01-06 | Morgan Stanley | $8 | 174% upside | |
| 2023-01-06 | Piper Sandler | $12 | 311% upside | |
| 2023-01-06 | BMO Capital | $7 | 139.7% upside | |
| 2023-01-05 | Truist FinancialRobyn Karnauskas | $7 | 139.7% upside | |
| 2022-12-15 | Goldman SachsAndrea Tan | $10 | 242.5% upside | |
| 2022-12-13 | Truist Financial | $46 | 1475.3% upside | |
| 2021-12-13 | OppenheimerMatthew Biegler | $135 | 4523.3% upside | |
| 2021-11-08 | CitigroupYigal Nochomovitz | $87 | 2879.5% upside | |
| 2021-11-05 | Roth CapitalAnthony Butler | $60 | 1954.8% upside | |
| 2021-10-25 | JefferiesMichael Yee | $145 | 4865.8% upside | |
| 2021-08-20 | Piper SandlerEdward Tenthoff | $113 | 3769.9% upside | |